Ipilimumab biosimilar (Gloria)

伊匹木单抗生物类似药（誉衡）

Report date: 2022/09/29 11:27:41

Base Information

Drug NameIpilimumab biosimilar (Gloria)
Drug Alias NameIpilimumabum biosimilar易普力姆玛生物类似药艾匹利木单抗生物类似药易普利姆玛生物类似药
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHarbin Gloria Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjingjinsirui Science & Technology Biology CorpHarbin Gloria Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A